BSX250103C89000
- 1.85
- 0.000.00%
Boston Scientific Newsroom
Needham Maintains Boston Scientific(BSX.US) With Hold Rating
BTIG Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $101
Bernstein Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $100
CCORF Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $101
Positive Long-Term Outlook for Boston Scientific Post-Axonics Acquisition: Buy Rating Affirmed
Bernstein Sticks to Their Buy Rating for Boston Scientific (BSX)
RBC Capital Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $105
RBC Capital Remains a Buy on Boston Scientific (BSX)
Evercore Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $100
BTIG Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $101
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Vivani Medical (VANI) and Merit Medical Systems (MMSI)
Wells Fargo Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $100
Truist Financial Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $110
RBC Capital Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $105
Truist Financial Maintains Boston Scientific(BSX.US) With Buy Rating, Announces Target Price $110
Morgan Stanley Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $100
Boston Scientific Analyst Ratings
JP Morgan Maintains Overweight on Boston Scientific, Raises Price Target to $110
Goldman Sachs Raises Price Target on Boston Scientific to $103 From $102, Maintains Buy Rating
Boston Scientific Is Maintained at Buy by TD Cowen